(+)-(4aR,10bR)-3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol hydrochloride manufacturers
|
| | (+)-(4aR,10bR)-3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol hydrochloride Basic information |
| Product Name: | (+)-(4aR,10bR)-3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol hydrochloride | | Synonyms: | (+/-)-PD 128,907 HYDROCHLORIDE;(+)-PD 128907 HYDROCHLORIDE;(+)-(4ar,10br)-3,4,4a,10b-tetrahydro-4-propyl-2h,5h-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol hydrochloride;(S)-(+)-(4aR,10bR)-3,4a,4,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-ol hydrochloride;(4aR,10bR)-3,4a,4,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-olhydrochloride;(4aR,10bR)-4-propyl-2,3,4,4a,5,10b-hexahydrochroMeno[4,3-b][1,4]oxazin-9-ol hydrochloride;(4aR,10bR)-rel-4-Propyl-2,3,4,4a,5,10b-hexahydrochroMeno[4,3-b][1,4]oxazin-9-ol;(+/-)-PD 128 | | CAS: | 300576-59-4 | | MF: | C14H19NO3HCl | | MW: | 285.77 | | EINECS: | | | Product Categories: | Dopamine receptor | | Mol File: | 300576-59-4.mol | ![(+)-(4aR,10bR)-3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol hydrochloride Structure](CAS/GIF/300576-59-4.gif) |
| | (+)-(4aR,10bR)-3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol hydrochloride Chemical Properties |
| storage temp. | Keep in dark place,Inert atmosphere,Room temperature | | solubility | ethanol: >10mg/mL | | form | solid | | color | off-white | | Water Solubility | Soluble to 10 mM in water | | InChIKey | DCFXOTRONMKUJB-QMDUSEKHSA-N |
| Safety Statements | 24/25 | | WGK Germany | 3 |
| | (+)-(4aR,10bR)-3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol hydrochloride Usage And Synthesis |
| Uses | (+)-PD 128907 Hydrochloride is a potent D3 receptor agonist. | | Biological Activity | Potent D 3 dopamine receptor agonist (K i = 2.3 nM). Displays 18-200-fold selectivity over other dopamine receptor subtypes. | | in vivo | (+)-PD 128907 significantly decreases dialysate DA levels in D3 knock out mice. The IC25 values are 61 nM and 1327 nM, respectively, for wild type and D3knock out mice. The ratio of the IC25 values shows that (+)-PD 128907 is 22 times more potent in decreasing dialysate DA levels in wild type as compared to mice lacking the D3 receptor. The D3 agonist evokes a dose related decrease in dialysate DA in wild type mice. Post-hoc analysis shows that all doses tested (0.03, 0.1 and 0.3 mg/kg) significantly inhibit dialysate DA. The IC25 values are 0.05 and 0.44 mg/kg for wild type and knock out mice, respectively, indicating that systemically administered (+)-PD 128907 is 9 times more potent in decreasing dialysate DA in the ventral striatum of wild type as compared to D3 knock out mice. Doses of 1 mg/kg or higher of (+)-PD 128907 markedly inhibits dialysate DA in both wild type and D3 knock out mice[3]. | | IC 50 | D3 Receptor; D2 Receptor | | storage | Store at +4°C |
| | (+)-(4aR,10bR)-3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol hydrochloride Preparation Products And Raw materials |
|